Last reviewed · How we verify
NCT06308731: EDX
Exercise-Induced Rates of Fat Oxidation with and Without Ingestion of a Caffeine-Based Energy Drink
NA trial testing Caffeine-Based Energy Drink in Substrate Oxidation in 15 participants. Completed in 16 September 2024.
16 September 2024
Quick facts
| Lead sponsor | Lindenwood University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | other |
| Enrollment | 15 |
| Start date | 19 January 2024 |
| Primary completion | 16 September 2024 |
| Estimated completion | 16 September 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Caffeine-Based Energy Drink
- Placebo
Conditions studied
- Substrate Oxidation — all drugs for Substrate Oxidation →
- Energy Expenditure — all drugs for Energy Expenditure →
- Reaction Time — all drugs for Reaction Time →
- Cognition — all drugs for Cognition →
Sponsor
Lindenwood University
Who can join
Adults 18 to 50, any sex, with Substrate Oxidation or Energy Expenditure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate acute changes in rates of fat oxidation during exercise with and without the ingestion of a caffeine-based energy drink.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06308731
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Caffeine-Based Energy Drink
Trials testing the same drug.
- NCT05998096 — A Randomized Study to Examine the Ability of a Caffeine-Based Energy Drink to Impact Energy Expenditure, Fat Oxidation, · NA · completed
Other Lindenwood University trials
Trials by the same sponsor.
- NCT07387991 — Evaluating the Ability of a Multi-Strain Postbiotic to Impact Inflammation, Immune Components, Gastrointestinal Symptoms · NA · not yet recruiting
- NCT07388264 — Impact of Weizmannia (Bacillus) Coagulans JBI-YZ6.3 on Gut Health and Fecal Microbiome Changes · NA · recruiting
- NCT07310108 — Evaluation of Cordyceps Militaris M2-116-04 for Its Potential Sport and Exercise Nutrition Applications in Healthy Activ · NA · completed
- NCT06672952 — Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Othe · NA · recruiting
- NCT07502924 — Dose-Response Impact of Geranylgeraniol (GG) Supplementation on Muscle Health · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06308731 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lindenwood University
- Last refreshed: 17 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06308731.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing